期刊文献+

ER、PR、P53及CerbB2蛋白在乳腺导管原位癌中的表达及意义 被引量:3

Expression of ER,PR,P53,CerbB2 in ductal carcinoma in situ of the breast and its significance
下载PDF
导出
摘要 目的探讨乳腺导管原位癌不同组织学分级中ER、PR、P53及CerbB2蛋白表达情况。方法收集80例乳腺导管原位癌标本,参照Van Nuys分类方法,对80例乳腺导管原位癌按核的分级、有无坏死进行组织学分级,并对所有标本行ER、PR、P53及CerbB2蛋白的免疫组化染色。结果低级别ER、PR、P53及CerbB2的阳性率分别为90.00%、85.00%、55.00%、25.00%;中级别ER、PR、P53及CerbB2的阳性率分别为88.50%、80.80%、46.20%、50.00%;高级别ER、PR、P53及CerbB2的阳性率分别为35.30%、29.40%、67.60%、82.40%。统计学分析ER、PR及CerbB2蛋白在低级别与高级别组,中级别与高级别组中表达差异有统计学意义(P<0.01)。结论ER、PR和CerbB2蛋白在乳腺癌的发展过程中起着重要作用,可以作为判断肿瘤分级较好的指标。 Objective To study the expression of ER,PR,P53 and CerbB2 in ductal carcinoma in situ(DCIS) of the breast and explore their relationship with the pathological grade.Methods A total of 80 samples of DCIS were collected.According to Van Nuys classification,all the samples were divided into three groups.The ER,PR,P53 and CerbB2 expression was examined by immunohistochemistry.Results The positive rates of ER,PR,P53 and CerbB2 were 90.00%,85.00%,55.00% and 25.00% respectively in the low grade group;The positive rates of ER,PR,P53 and CerbB2 were 88.50%,80.80%,46.20% and 50.00% respectively in the median grade group;The positive rates of ER,PR,P53 and CerbB2 were 35.30%,29.40%,67.60% and 82.40% respectively in the high grade group.The ex pression of ER and PR in the low and median grade group was significantly higher than that in the high grade group.Conversely,the expression of CerbB2 in the low and median grade group was significantly lower than that in the high grade group.Conclusion ER,PR and CerbB2 may play an important part during the development process of breast cancers.They can be served as ideal biomarkers for the classification of pathological grade in breast tumors.
出处 《中国现代医生》 2013年第10期85-87,共3页 China Modern Doctor
基金 浙江省医药卫生科技计划(2011KYA033)
关键词 乳腺肿瘤 ER PR P53 CERBB2 免疫组织化学 Breast tumor ER PR P53 CerbB2 Immunohistochemistry
  • 相关文献

参考文献10

二级参考文献54

  • 1张景丽,张红英,魏兵,郎志强,步宏.细胞角蛋白在乳腺导管内增生性病变鉴别诊断中的应用[J].中华病理学杂志,2004,33(4):316-319. 被引量:9
  • 2徐彬,方志沂,刘君,李强.ERα和ERβ在乳腺癌和癌旁组织内的表达[J].实用肿瘤杂志,2006,21(2):149-151. 被引量:2
  • 3韩晶,王培军,汤如勇,张静,方建萍.HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J].第二军医大学学报,2006,27(11):1268-1269. 被引量:4
  • 4Tavassoli FA ,Snares J . Myoepithelial lesions. In:Tavassoli FA , Devileepeds World Health Organization Classification of Tumours. In :WHO , ed Pathology and genetics of tumours of the breast and female genital organs[ M]. Lyon : IARC Press,2003:67-71.
  • 5Jukkola A, Bloigu R, Soini Y, et al . CerbB positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease[J]. Eur J Cancer,200l ,37 ( 8 ) :347-354.
  • 6Raft JP, Raider L, Malik U. et al. Phase Ⅱ study of weeklv docetaxel alone or in combination with trastuzumab in patient swith metastatic breast cancer[J].Clin Breast Cancer, 2004,4 ( 2 ) : 420-427.
  • 7[4]Hoffman WH,Blade S,Zilfoi JT et al.Transcriptional repmsion of the antiapoptotic survivin gene by wild type P53.Biol Chen,2002,277(5):3247.
  • 8[6]]Montero S,Guzman C,Vargas C,et al.Prcgnoxtic value of cytoso hc P53 protein in breast cancer.Tumor Biol,200l,22(5):337.
  • 9[8]Hail PA,Lotl DA,Woods AL,et al.Proliferating cell nuclear antigen (PCNA)immunolocalization in paraffin sections:an in dex of cell proliferation with evidence of deregulated expression in some neoplasms.J Pathol,1990,162(4):285.294.
  • 10Tavassoli FA, Devilee P. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and femal genital organs[ M ]. Lyon : LARC Press, 2003.10.

共引文献54

同被引文献51

  • 1洪常华,韩德昌,杨新宇,姬颖彬,田震静,吴玉辉,侯坤.乳腺MRI与乳腺X线诊断导管原位癌的临床效果[J].中国老年学杂志,2015,35(2):376-377. 被引量:12
  • 2姜英,陈杰.乳腺导管上皮内瘤变(DIN)[J].诊断病理学杂志,2005,12(6):463-466. 被引量:9
  • 3赵亮,张魁.乳腺原位癌28例临床分析[J].徐州医学院学报,2006,26(4):355-357. 被引量:1
  • 4Barrel DP. MicroRNAs:target recognition and regulatory functions[J]. Cell,2009,136(2) :215-233.
  • 5Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of mi- croRNA aberrant expression in and sera from patients with breast tu- mot[J]. Gynecol Oncol,2010,119(3 ):586-593.
  • 6Liang Z,LI Y,Huang K,et al. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN[J]. Pharm Res,2011,28(12) : 1147-1154.
  • 7Michael P,Gantier H,James Stunden,et al. A miR-19 regulon that controls NF-κB signaling[J]. Nucleic Acids Research, 2012,40 ( 16 ) : 8048-8058.
  • 8Sarah E Pinder. Ductal carcinoma in situ (DCIS) : pathological features, differential diagnosis, prognostic factors and specimen evaluation[J]. Modem Pathology, 2010,23 (2) : $8 - S13.
  • 9Lagios MD, Silverstein ML Ductal carcinoma in situ: recent history and areas of controversy[ J]. Breast J, 2015 ,21 ( 1 ) :21 - 26.
  • 10Burkhardt L, Groh T], Hermann I, et al. Gone amplification in duets] eareinoma in situ of the breast [ J ]. Breast Cancer Res Treat,2010,123 ( 3 ) : 757 - 765.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部